Cepheid (NASDAQ:CPHD)
| 38.27 Data as of May 17 |  -0.25 / -0.65%Today’s Change | 28.12 Today|||52-Week Range 46.00 | +13.02% Year-to-Date |
Latest CPHD News | Press Releases
| Neutral Rating Restated for Cepheid - Analyst Blog May 13 / Zacks.com |
Today’s Trading
| Previous close | 38.52 |
| Today’s open | 38.63 |
| Day’s range | 38.09 - 38.80 |
| Volume | 379,964 |
| Average volume (3 months) | 409,127 |
| Market cap | $2.6B |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/17/2013
Growth & Valuation
| Earnings growth (last year) | -850.00% |
| Earnings growth (this year) | +103.87% |
| Earnings growth (next 5 years) | +15.00% |
| Revenue growth (last year) | +19.65% |
| P/E ratio | NM |
| Price/Sales | 6.71 |
| Price/Book | 10.30 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BIOBio-Rad Laboratories... | -1.11 | -0.95% |
| BRKRBruker Corp | +0.08 | +0.48% |
| FEICFEI Co | +2.38 | +3.36% |
| PKIPerkinElmer Inc | +0.21 | +0.66% |
Data as of 4:02pm ET, 05/17/2013
Financials
| Next reporting date | July 25, 2013 |
| EPS forecast (this quarter) | -$0.04 |
| Annual revenue (last year) | $332.1M |
| Annual profit (last year) | -$20.0M |
| Net profit margin | -6.04% |
Profile
Sector Health Technology |
Industry Biotechnology |
Chairman & Chief Executive Officer John L. Bishop |
Chief Operating Officer & Executive Vice President Humberto Reyes |
Corporate headquarters Sunnyvale, California |
Forecasts
